Here are six things to know from the report:
1. The company’s total revenue for the second quarter is expected to hit $33.5 million, down 6 percent for the same period last year.
2. Orthobiologics revenue is projected to increase 1 percent to $17 million.
3. The spinal fusion hardware revenue will be down 13 percent to $16.5 million for the second quarter.
4. Full-year revenue is expected to reach $133 million to $139 million, flat or down 4 percent compared with the same period last year. This is unchanged from the previous guidance Integra LifeSciences projected.
5. SeaSpine became an independent company July 1 and is investing in innovation and growth initiatives. The orthobiologics platform is the leading platform.
6. President and CEO Keith Valentine reported the company has a robust research and development pipeline that includes spinal fusion hardware products recently launched. The company expects to launch additional products in the second half of this year.
More articles on orthopedic devices:
Smith & Nephew to build US headquarters in Fort Worth
Nevro announces positive results from SENZA system study
Is Stryker next for a big transaction?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
